162 related articles for article (PubMed ID: 28678611)
1. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review.
Han T; Luan Y; Xu Y; Yang X; Li J; Liu R; Li Q; Zheng Z
Cancer Biol Ther; 2017 Sep; 18(9):635-639. PubMed ID: 28678611
[TBL] [Abstract][Full Text] [Related]
2. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report.
Dong M; Bi J; Liu X; Wang B; Wang J
Medicine (Baltimore); 2016 Aug; 95(31):e4368. PubMed ID: 27495042
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment using apatinib in intractable brain edema: A case report and literatures review.
Song Y; Liu B; Guan M; Liu M
Cancer Biol Ther; 2018; 19(12):1093-1096. PubMed ID: 30081717
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of apatinib in desmoplastic small round cell tumor: a case report and literature review.
Shi C; Feng Y; Zhang LC; Ding DY; Yan MY; Pan L
BMC Cancer; 2018 Mar; 18(1):338. PubMed ID: 29587657
[TBL] [Abstract][Full Text] [Related]
5. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
[TBL] [Abstract][Full Text] [Related]
7. Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.
Li CM; Liu ZC; Bao YT; Sun XD; Wang LL
World J Gastroenterol; 2017 Nov; 23(41):7478-7488. PubMed ID: 29151702
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of low-dose Apatinib in the management of stage IV luminal-type breast cancer: a case report and literature review.
Lv X; Chen J; Yi T; Lu H; Liu J; Yu D
Anticancer Drugs; 2021 Sep; 32(8):773-778. PubMed ID: 34145174
[TBL] [Abstract][Full Text] [Related]
9. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
10. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
11. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
12. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.
Yao H; Chen X; Tan X
BMC Cancer; 2021 Apr; 21(1):449. PubMed ID: 33892656
[TBL] [Abstract][Full Text] [Related]
14. Effective apatinib treatment of pleomorphic liposarcoma: A case report.
Yan P; Sun ML; Sun YP; Liu CY
Medicine (Baltimore); 2017 Aug; 96(33):e7771. PubMed ID: 28816958
[TBL] [Abstract][Full Text] [Related]
15. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
17. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
18. Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Zhou N; Liu C; Hou H; Zhang C; Liu D; Wang G; Liu K; Zhu J; Lv H; Li T; Zhang X
Oncotarget; 2016 Nov; 7(44):72373-72379. PubMed ID: 27738308
[TBL] [Abstract][Full Text] [Related]
19. Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report.
Sun H; Xiao M; Liu S; Shi R
Medicine (Baltimore); 2018 Jul; 97(27):e11036. PubMed ID: 29979376
[TBL] [Abstract][Full Text] [Related]
20. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
